RespiratoryRegeneron
Regeneron Reports Phase 3 LIBERTY NPS Results for Dupixent in Chronic Rhinosinusitis
BMI
Biotechnology Media Insights
Editorial Team · September 20, 2023
Regeneron and Sanofi announce Phase 3 LIBERTY NPS trial results showing Dupixent significantly reduces nasal polyp burden in chronic rhinosinusitis.
Regeneron and Sanofi today announced results from the Phase 3 LIBERTY NPS trial evaluating Dupixent (dupilumab) in patients with chronic rhinosinusitis with nasal polyps. The trial met its primary endpoints, demonstrating significant reductions in nasal polyp score and nasal congestion compared to placebo.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.